

KSE/N-1238

N O T I C E

March 05, 2015

Reproduced hereunder the letter No. KSE/C-49-1404 dated February 26, 2015 sent to GLAXOSMITHKLINE PAKISTAN LIMITED, by the Exchange and response received from the Company vide their letter dated March 04, 2015 for information of all concerned.

(Copy of the same is also available on our Website www.kse.com.pk).

**KARACHI STOCK EXCHANGE LIMITED**

STOCK EXCHANGE BUILDING, STOCK EXCHANGE ROAD, KARACHI-74000, PAKISTAN.

UAN : 111-001-122 FAX : 32410825

WEBSITE: www.kse.com.pk E-mail: gm@kse.com.pkRef. No. **C-49-1404**
KSE/

February 26, 2015

Courier Service

Fax No: 32314898-32311122

The Company Secretary
GlaxoSmithKline Pakistan Limited
Sykes Building
35-Dockyard Road, West Wharf
Karachi


**Subject: Disclosure of Material Information - Major global three-part
Inter-conditional transaction between GlaxoSmithKline plc U.K. and
Novartis A.G, Switzerland**

Dear Sir,

Please refer to your letter dated February 19, 2015 and February 25, 2015 on the subject.

We shall appreciate if you kindly share with us the Scheme / salient features of De-merger of the Consumer Healthcare Business approved by your Board of Directors in their meeting held on February 25, 2015, particularly with reference to shareholders point of view as to whether the De-merger will take place in the form of corporate body to be incorporated / listed on the Exchange or some other mode has been decided.

Yours sincerely,


Muhammad Ghufan
Deputy General Manager

Copy to:
Managing Director – KSE